Vaccine Company, Inc. is a biotechnology firm focused on vaccine development using its proprietary In Vivo Nanoparticle (IVN) technology. This platform enables virus-like particle antigen presentation without conventional manufacturing processes. The company’s lead candidate is a five-antigen prophylactic vaccine against Epstein-Barr virus (EBV), currently Phase 1-ready, with potential applications in preventing infectious mononucleosis and reducing EBV-associated risks such as multiple sclerosis and certain malignancies.
